Key Highlights
- First-quarter 2026 net loss decreased to $5.51M from $8.20M in the prior-year period.
- Loss per diluted share improved significantly to $(6.95) versus $(57.76) year-over-year.
- Cash position of $9.2M at quarter-end, supported by a $10.5M February capital raise.
- ERNA-101 demonstrated complete tumor elimination and 100% survival rates in combination with PD-1 therapy during preclinical testing.
- Company executed a 1-for-25 reverse split in May and submitted a $50M shelf registration featuring an ATM component for capital flexibility.
On May 11, Ernexa Therapeutics (ERNA) disclosed its first-quarter 2026 financial performance, triggering a dramatic 78% single-day stock price surge. The cell therapy developer, currently in preclinical stages, demonstrated financial progress and provided fresh details on its therapeutic programs.
Ernexa Therapeutics Inc., ERNA
For the three months ended March 31, 2026, the firm recorded a net loss of $5.51 million, representing a notable decline from the $8.20 million deficit reported during the corresponding 2025 quarter. This reflects a year-over-year reduction of $2.70 million.
The diluted per-share loss registered at $(6.95), marking substantial progress from the $(57.76) figure posted in the first quarter of 2025. The prior year’s metric reflects share counts before the company’s recent 1-for-25 reverse consolidation, which became effective on May 4, 2026.
Total operating expenditures reached $5.6 million during the reporting period. This breakdown encompassed $1.9 million allocated to research and development initiatives, $1.6 million directed toward general and administrative functions, and a $2.0 million non-cash goodwill impairment charge.
The company closed the quarter holding $9.2 million in cash and equivalents. This balance benefited from a February equity financing transaction that generated approximately $10.5 million in gross capital through an offering of common shares, pre-funded warrants, and performance-based warrants.
Company leadership acknowledged that the approximate $8.3 million cash balance as of April 30 remains insufficient to fund projected operational requirements throughout the coming 12-month period.
Addressing this capital shortfall, Ernexa submitted a $50 million universal shelf registration statement and established an at-the-market offering facility, which management anticipates will provide access to as much as $9.2 million in additional funding.
Lead Candidate ERNA-101 Delivers Encouraging Preclinical Outcomes
Regarding clinical development activities, the company’s primary oncology asset, ERNA-101, demonstrated measurable tumor size reduction in animal models. More significantly, when administered alongside PD-1 checkpoint inhibitor therapy, the combination achieved complete tumor elimination and 100% sustained survival in the experimental studies disclosed.
These findings represent preclinical-stage data—human clinical validation remains the critical next milestone. Management disclosed that it has concluded a pre-Investigational New Drug (IND) consultation with the Food and Drug Administration and intends to file an IND application during the latter portion of 2026, with an investigator-initiated Phase I clinical study projected to commence in the second half of the year.
The organization is simultaneously progressing ERNA-201, an interleukin-10-secreting induced mesenchymal stem cell therapy designed for autoimmune disease applications, while actively exploring collaborative partnerships and grant opportunities to fund continued research.
International Expansion Efforts and Regulatory Compliance Measures
Beyond pipeline advancement, Ernexa secured admission to a specialized Japan-focused trade acceleration initiative designed to facilitate commercial entry into the Japanese healthcare market.
The reverse stock consolidation, which resulted in 1,166,333 outstanding common shares as of May 8, 2026, served partially as a regulatory compliance strategy. Management believes this action will enable the company to satisfy Nasdaq minimum bid price listing requirements.
As of the March 31, 2026 balance sheet date, Ernexa maintained 1,166,333 common shares outstanding on a retroactively adjusted basis reflecting the reverse split.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
